Welcome to the European Association for Cancer Research
Connecting cancer researchers together
Next Generation Cancer Therapies
Virtual Event, Worldwide : 24 - 25 September 2024
Scientific programme
To download and print the programme, use the links below.
Listed times are in Central European Time (CEST)
WELCOME TO DAY ONE
Introduction: Steve Wedge
Session 1: Targeting RAS
Session Chair: Steve Wedge
Hitoshi Iikura Chugai Pharmaceutical Co. Ltd, Yokohama, Japan
The development of cyclic peptides and the discovery of the LUNA18 RAS inhibitor
Q&A 13:25-13:40
Jan Smith Revolution Medicines, California, USA
Targeting the active (GTP-bound) forms of RAS
Q&A 14:00-14:15
REFRESHMENT BREAK
Session 2: Molecular Glues
Session Chair: Susan Critchlow
Alessio Ciulli University of Dundee / Amphista Therapeutics, Dundee, UK
How PROTAC degraders work: Molecular recognition and design principles
Q&A 14:50 - 15:05
Saverio Alberti Università di Messina, Messina, Italy
Proffered Paper 1: Hu2G10 antibody-drug conjugates target cleaved-activated Trop-2 in cancer cells and show therapeutic efficacy in vivo
Q&A 15:15-15:25
Romi Gupta The University of Alabama at Birmingham, Birmingham, USA
Proffered Paper 2: ATAD2 is a driver and a therapeutic target in ovarian cancer
Q&A 15:35-15:45
REFRESHMENT BREAK
Session 3: Targeting mutant p53
Session Chair: Mark Pearson
Ecaterina E Dumbrava MD Anderson Cancer Centre, Texas, USA
p53 Y220C inhibitor
Q&A 16:20 - 16:35
POSTER SPOTLIGHTS
2 top abstracts presented as 3-minute flash talks
TRANSITION BREAK
VIRTUAL POSTER SESSION
Listed times are in Central European Time (CEST)
WELCOME TO DAY TWO
Session 4: PROTAC degraders
Session Chair: Susan Critchlow
Nicolas Thoma FMI, Switzerland
Oncogenic transcription factors – how they work (and how to get rid of them)
Q&A 14:25-14:40
Elisa Rioja Blanco ETH Zurich, Zurich, Switzerland
Proffered Paper 3: Terbium-161 radioimmunotherapy as an innovative treatment for CD30+ lymphomas
Q&A 14:50 - 15:00
REFRESHMENT BREAK
Session 5: Phenotypic screening
Session Chair: Mark Pearson
Nunki Hassan University of Sydney, Sydney, Australia
Proffered Paper 4: Targeting PAR1 for leukemic stem cell eradication: a promising new treatment strategy for blood cancers
Q&A 15:25 - 15:35
Aimee Iberg Recursion, Salt Lake City, USA
Unbiased phenotypic screening to discover next generation therapies
Q&A 15:55 - 16:10
REFRESHMENT BREAK
Session 6: Antibody - drug conjugates and reactivation of wild-type p53
Session Chair: Erica Jackson
Puja Sapra SVP, Biologics Engineering and Oncology Targeted Discovery, AstraZeneca, Gaithersburg, US
The renaissance of ADC in oncology
Q&A 16:45 - 17:00
Maria Ahn Astex Pharmaceuticals, Cambridge, UK
ASTX295: designing a bone marrow sparing MDM2-p53 inhibitor
Q&A 17:20 - 17:35
DISCUSSION SESSION
Where will the next generation of cancer therapies come from – opportunities and challenges?
Steve Wedge, Newcastle University, UK; Susan Critchlow, AstraZeneca, Cambridge, UK, Erica Jackson, Scorpion Therapeutics, Boston, USA, Mark Pearson, Boehringer-Ingelheim, Austria
SUMMARY AND CLOSE
Key dates
Abstract submission deadline:
29 July 2024
Registration deadline:
09 September 2024
